Anne Klibanski

17.6k total citations · 4 hit papers
141 papers, 11.3k citations indexed

About

Anne Klibanski is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Epidemiology. According to data from OpenAlex, Anne Klibanski has authored 141 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Endocrinology, Diabetes and Metabolism, 40 papers in Surgery and 17 papers in Epidemiology. Recurrent topics in Anne Klibanski's work include Pituitary Gland Disorders and Treatments (113 papers), Growth Hormone and Insulin-like Growth Factors (92 papers) and Adrenal and Paraganglionic Tumors (39 papers). Anne Klibanski is often cited by papers focused on Pituitary Gland Disorders and Treatments (113 papers), Growth Hormone and Insulin-like Growth Factors (92 papers) and Adrenal and Paraganglionic Tumors (39 papers). Anne Klibanski collaborates with scholars based in United States, Italy and United Kingdom. Anne Klibanski's co-authors include Beverly M. K. Biller, Brooke Swearingen, Laurence Katznelson, Шломо Мелмед, Nicholas T. Zervas, David Schoenfeld, Steven Grinspoon, Fred G. Barker, Philippe Chanson and Felipe F. Casanueva and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Anne Klibanski

138 papers receiving 10.9k citations

Hit Papers

A Consensus on Criteria f... 1996 2026 2006 2016 2010 1996 1998 2018 100 200 300 400 500

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Anne Klibanski 9.0k 3.1k 1.9k 1.4k 1.1k 141 11.3k
Beverly M. K. Biller 11.3k 1.3× 4.1k 1.3× 1.2k 0.6× 1.3k 0.9× 899 0.9× 221 13.7k
Laurence Katznelson 6.5k 0.7× 2.4k 0.8× 1.4k 0.8× 921 0.6× 807 0.8× 146 7.9k
Alberto M. Pereira 11.6k 1.3× 4.1k 1.3× 1.7k 0.9× 1.4k 1.0× 1.2k 1.1× 342 14.2k
Laura De Marinis 4.5k 0.5× 1.4k 0.5× 1.1k 0.6× 1.1k 0.8× 502 0.5× 245 6.7k
G. M. Besser 8.2k 0.9× 3.1k 1.0× 2.2k 1.2× 1.4k 1.0× 746 0.7× 259 13.0k
Ken K. Y. Ho 8.6k 1.0× 1.5k 0.5× 1.1k 0.6× 2.1k 1.5× 347 0.3× 186 11.5k
Janet Schlechte 3.9k 0.4× 1.7k 0.6× 869 0.5× 501 0.4× 435 0.4× 97 6.4k
Gudmundur Johannsson 9.7k 1.1× 1.6k 0.5× 708 0.4× 1.9k 1.3× 498 0.5× 327 12.3k
Martin O. Savage 8.9k 1.0× 3.4k 1.1× 1.2k 0.6× 2.7k 1.9× 447 0.4× 268 12.8k
Alberto Angeli 4.2k 0.5× 2.9k 1.0× 540 0.3× 1.0k 0.7× 372 0.4× 209 8.3k

Countries citing papers authored by Anne Klibanski

Since Specialization
Citations

This map shows the geographic impact of Anne Klibanski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Klibanski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Klibanski more than expected).

Fields of papers citing papers by Anne Klibanski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Klibanski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Klibanski. The network helps show where Anne Klibanski may publish in the future.

Co-authorship network of co-authors of Anne Klibanski

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Klibanski. A scholar is included among the top collaborators of Anne Klibanski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Klibanski. Anne Klibanski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wass, John, Anne Klibanski, Шломо Мелмед, et al.. (2025). A Consensus Statement on acromegaly therapeutic outcomes. UNC Libraries.
2.
Zhao, Wenxiu, Alexander T. Faje, Brooke Swearingen, et al.. (2022). Sprouting Angiogenesis in Human Pituitary Adenomas. Frontiers in Oncology. 12. 875219–875219. 5 indexed citations
3.
Swearingen, Brooke, et al.. (2018). Characterization of cyclic Cushing's disease using late night salivary cortisol testing. Clinical Endocrinology. 89(3). 336–345. 11 indexed citations
4.
Swearingen, Brooke, et al.. (2016). Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center. Pituitary. 19(4). 437–447. 7 indexed citations
5.
Giustina, Andrea, Philippe Chanson, David L. Kleinberg, et al.. (2014). Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Reviews Endocrinology. 10(4). 243–248. 271 indexed citations
6.
Ajmal, Adnan, et al.. (2013). The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly. Pituitary. 17(4). 366–373. 17 indexed citations
8.
Мелмед, Шломо, Felipe F. Casanueva, Anne Klibanski, et al.. (2012). A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 16(3). 294–302. 235 indexed citations
9.
Valassi, Elena, Beverly M. K. Biller, Brooke Swearingen, et al.. (2010). Delayed Remission after Transsphenoidal Surgery in Patients with Cushing’s Disease. The Journal of Clinical Endocrinology & Metabolism. 95(2). 601–610. 115 indexed citations
10.
Miller, Karen K., T Wexler, Pouneh K. Fazeli, et al.. (2010). Growth Hormone Deficiency after Treatment of Acromegaly: A Randomized, Placebo-Controlled Study of Growth Hormone Replacement. The Journal of Clinical Endocrinology & Metabolism. 95(2). 567–577. 53 indexed citations
11.
Klibanski, Anne, Шломо Мелмед, David R. Clemmons, et al.. (2009). The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. Pituitary. 13(3). 266–286. 5 indexed citations
12.
Harris, Philip E., Anthony J. Good, Gary Layton, et al.. (2007). A comparison between the efficacy and safety of pegvisomant to that of octreotide LAR in patients with acromegaly. 14. 1 indexed citations
13.
Chaidarun, Sushela & Anne Klibanski. (2002). Gonadotropinomas. Seminars in Reproductive Medicine. 20(4). 339–348. 38 indexed citations
14.
Klibanski, Anne, Ken K. Y. Ho, Pamela U. Freda, et al.. (2001). State-of-the-Art Strategies for the Diagnosis and Management of Acromegaly. The Endocrinologist. 11(3). 223–232. 4 indexed citations
15.
Miller, Karen K., et al.. (2001). Androgen Deficiency in Women with Hypopituitarism1. The Journal of Clinical Endocrinology & Metabolism. 86(2). 561–567. 84 indexed citations
16.
Newman, Connie B., Шломо Мелмед, Ajax E. George, et al.. (1998). Octreotide as Primary Therapy for Acromegaly1. The Journal of Clinical Endocrinology & Metabolism. 83(9). 3034–3040. 14 indexed citations
17.
Swearingen, Brooke, Fred G. Barker, Laurence Katznelson, et al.. (1998). Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1. The Journal of Clinical Endocrinology & Metabolism. 83(10). 3419–3426. 509 indexed citations breakdown →
18.
Biller, Beverly M. K., et al.. (1989). Mechanisms of Osteoporosis in Adult and Adolescent Women with Anorexia Nervosa*. The Journal of Clinical Endocrinology & Metabolism. 68(3). 548–554. 330 indexed citations
19.
Finkelstein, Joel S., Anne Klibanski, R. Neer, & W F Crowley. (1988). Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism ihh. Clinical research. 36(3). 384. 1 indexed citations
20.
Barbieri, Robert L., David S. Cooper, Gilbert H. Daniels, et al.. (1985). Prolactin response to thyrotropin-releasing hormone (TRH) in patients with hypothalamic-pituitary disease. Fertility and Sterility. 43(1). 66–73. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026